-- InSilico Medicine (HKG:3696) granted a little over 3.7 million restricted share units (RSUs) to certain participants under a post-IPO RSU scheme, according to a Tuesday Hong Kong bourse filing.
The granting of the RSUs is subject to the fulfillment of the relevant performance targets, the AI-driven drug discovery and development company said.
The firm now has around 24.2 million shares available for future grants under its RSU and share option incentive plans, of which 2.8 million shares will be available for future grant to service providers within the scheme mandate limit.